Skip to content

Betamethasone LA effects versus Dexamethasone in treatment of Sudden Sensory Hearing Loss

A comparison of effects of intratympanic Dexamethasone and intratympanic Betamethasone LA therapy for patients with Idiopathic Sudden Sensorineural Hearing Loss: A randomized clinical trial study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2017012832069N2
Enrollment
94
Registered
2017-08-17
Start date
2017-05-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sudden sensorineural hearing loss. Sudden idiopathic hearing loss

Interventions

Intervention 1: Intervation group: Using LA Betamethasone 0.4-0.6 cc for Intratympanic injection that performed 6 injections twice aweek. Intervention 2: Control group : Using Dexamethasone 0.4-0.6
Treatment - Drugs
Intervation group: Using LA Betamethasone 0.4-0.6 cc for Intratympanic injection that performed 6 injections twice aweek.
Control group : Using Dexamethasone 0.4-0.6 cc for Intratympanic injection that performed 6 injections twice aweek.

Sponsors

Vice chancellor for research, Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 18-70 years old; patient with SSHL and history of systemic corticosteroids treatment without response to it; whitout history of ear disease; SSHL without certain causes. Exclusion criteria: pathology in the middle ear (tympanic membrane perforation, surgery on the ear) bilateral SSHL; previous intratympanic injection for the same disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Hearing cutoff. Timepoint: Before intervation, after intervation at force,1month after intervation,2months after the end of the intervation,6months after the end of the intervation. Method of measurement: PTA.

Secondary

MeasureTime frame
Vertigo. Timepoint: After the end of the intervation at force,1month and 2months and 6months after the end of the intervation. Method of measurement: Questionary.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDoctor Shima Hajibegloo

Tehran University Of Medical Sciences

dr.hbegloo@gmail.com+98 21 6670 6106

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026